Recent advances in the treatment and monitoring of HIV-1 infection have substantially diminished HIV-associated illness and mortality; however the management of HIV-infected patients has become increasingly complex. We are conducting studies that: (1) define the role of Hepatitis C viral response to pegylated interferon-based therapy (2) evaluate novel therapeutic strategies in the management of Hepatitis C virus among HIV co-infected individuals, and (3) develop novel genomic and proteomic markers that predict Hepatitis C viral response to existing and newer therapies. Analyses of the kinetics of the viral response to Hepatitis C therapy in Hepatitis C/HIV co-infected individuals suggest that it may be possible to predict long term response to anti-Hepatitis C therapy based on the initial response of the level of Hepatitis C virus in the plasma. Using combination therapy of pegylated interferon together with ribavirin in these subjects, we are determining whether genomic and proteomic markers can predict response to therapy prior to initiation of treatment. Another clinical trial will determine whether more frequent doses of pegylated interferon in combination with ribavirin can enhance the viral kinetic response to Hepatitis C therapy in persons with Hepatitis C infection and HIV infection. A new clinical trial using albumin-conjugated interferon alpha (Albuferon) to treat Hepatitis C among HIV infected patients will begin enrollment later this year.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Intramural Research (Z01)
Project #
1Z01AI000390-23
Application #
7299927
Study Section
(LIR)
Project Start
Project End
Budget Start
Budget End
Support Year
23
Fiscal Year
2006
Total Cost
Indirect Cost
Name
Niaid Extramural Activities
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Petersen, Tess; Lee, Yu-Jin; Osinusi, Anu et al. (2016) Interferon Stimulated Gene Expression in HIV/HCV Coinfected Patients Treated with Nitazoxanide/Peginterferon-Alfa-2a and Ribavirin. AIDS Res Hum Retroviruses 32:660-7
Shrivastava, Shikha; TrehanPati, Nirupama; Kottilil, Shyam et al. (2013) Decline in immature transitional B cells after hepatitis B vaccination in hepatitis B positive newborns. Pediatr Infect Dis J 32:792-4
Nussenblatt, Veronique; McLaughlin, Mary; Rehm, Catherine A et al. (2007) Immunodeficiency and intrinsic IFN resistance are associated with viral breakthrough to HCV therapy in HIV-coinfected patients. AIDS Res Hum Retroviruses 23:1354-9
Neumann, Au; Polis, Ma; Rozenberg, L et al. (2007) Differential antiviral effect of PEG-interferon-alpha-2b on HIV and HCV in the treatment of HIV/HCV co-infected patients. AIDS 21:1855-65
Meyers, Jennifer Hartt; Justement, J Shawn; Hallahan, Claire W et al. (2007) Impact of HIV on cell survival and antiviral activity of plasmacytoid dendritic cells. PLoS ONE 2:e458
Malaspina, Angela; Moir, Susan; Chaitt, Doreen G et al. (2007) Idiopathic CD4+ T lymphocytopenia is associated with increases in immature/transitional B cells and serum levels of IL-7. Blood 109:2086-8
Kottilil, Shyam; Jackson, Julia O; Reitano, Kristin N et al. (2007) Innate immunity in HIV infection: enhanced susceptibility to CD95-mediated natural killer cell death and turnover induced by HIV viremia. J Acquir Immune Defic Syndr 46:151-9
Wu, Lynne; Kottilil, Shyam; Lempicki, Richard et al. (2006) Hepatic histologic response (HR) to combination therapy among HCV/HIV-coinfected individuals: interferon induces HR independent of sustained virologic response (SVR). AIDS Res Hum Retroviruses 22:1091-8
Lempicki, R A; Polis, M A; Yang, J et al. (2006) Gene expression profiles in hepatitis C virus (HCV) and HIV coinfection: class prediction analyses before treatment predict the outcome of anti-HCV therapy among HIV-coinfected persons. J Infect Dis 193:1172-7
Kottilil, Shyam; Shin, Kyungmin; Jackson, Julia O et al. (2006) Innate immune dysfunction in HIV infection: effect of HIV envelope-NK cell interactions. J Immunol 176:1107-14

Showing the most recent 10 out of 52 publications